No Increase in Cardiovascular Events with JAK Inhibitors in IBD Patients Save
UMKC researchers have compared the use of JAK inhibitors versus tumor necrosis factor (TNF) blockers in inflammatory bowel disease (IBD) patients, but failed to see an increase in major adverse cardiovascular events (MACE) in JAKi vs TNFi use in IBD.
Findings of an abstract presented at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting in October 2024, looked at rates of MACE and venous thromboembolism (VTE) within one year of taking JAKi or TNFi.
Data from the TriNetX database included a total of 3,740 IBD patients taking JAK inhibitors were propensity-matched with 3,740 patients taking TNF blockers. The study excluded those with prior cardiovascular events.
- MACE: no significant difference between JAK inhibitors and TNF inhibitors (1.76% versus 1.94%, respectively).
- VTE: No difference was found between the two groups
- No differences between patients with ulcerative colitis versus Crohn’s disease on these drugs
These observational cohort findings suggest JAK inhibitors do not increase the risk for MACE or VTE in patients with ulcerative colitis or Crohn’s disease.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.